



## **Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series**

Registration Link for Presentation and live Q&A to take place, Thursday, November 7 at 12:00 pm EST

Marlborough Massachusetts--(Newsfile Corp. - November 1, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company creating new pathways towards a cancer-free future by using its INTASYL<sup>®</sup> siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells announced today that management will present in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.

Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present on Thursday, November 7 at 12:00 pm EST. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at <https://www.renmarkfinancial.com/vndrs>.

Phio Pharmaceuticals welcomes stakeholders, investors, and other individual followers to register and attend this live event.

**REGISTER HERE:** [Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications](#)

**If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.**

### **About Phio Pharmaceuticals Corp.**

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company and a pioneer in the RNAi revolution advancing its proprietary INTASYL siRNA gene silencing technology to create pathways towards a cancer-free future. INTASYL can target and silence virtually any gene with high degree of specificity across a wide range of cell types and tissues. INTASYL is designed to enhance the ability of immune cells to more effectively kill tumor cells. INTASYL is designed to enhance adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology that does not require formulation enhancements or manipulations to reach its target.

Phio's lead clinical program, PH-762, is an INTASYL compound that silences PD-1. PH-762 is a potential non-surgical treatment for skin cancers. The on-going Phase 1b study (NCT# 06014086) received FDA clearance for an Investigational New Drug (IND) to evaluate PH-762 in the treatment of cutaneous SCC, melanoma and Merkel cell carcinoma.

For additional information, visit the Company's website, [www.phiopharma.com](http://www.phiopharma.com).

### **Forward Looking Statements**

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to*

*predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.*

**Contact:**

**Phio Pharmaceuticals Corp.**

Jennifer Phillips: [jphillips@phiopharma.com](mailto:jphillips@phiopharma.com)

Corporate Affairs

**Remark Financial Communications Inc.**

James R. Kautz: [jkautz@remarkfinancial.com](mailto:jkautz@remarkfinancial.com)

Tel: (416)-644-2020 or (212)-812-7680

[www.remarkfinancial.com](http://www.remarkfinancial.com)



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/228417>

11/1/2024 7:45:00 AM